SCHEMBL3019119

SCHEMBL3019119

COc1cccc(-c2csc(N3CCC(S(=O)(=O)c4c(C)cc(C)cc4C)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.56
ALDH1A1 P00352 10/20 0.56
LMNA P02545 10/20 0.56
MAPK1 P28482 6/20 0.56
HSD17B10 Q99714 4/20 0.56
TP53 P04637 3/20 0.56
USP2 O75604 1/20 0.56
RECQL P46063 1/20 0.56
TSHR P16473 1/20 0.56
HPGD P15428 1/20 0.53
KMT2A Q03164 8/20 0.52
MEN1 O00255 7/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
HTT P42858 5/20 0.51
GAA P10253 2/20 0.51
NPSR1 Q6W5P4 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008287 0.91 MAPT (0.56) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3016543 0.91 SMN1; SMN2 (0.47) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3015749 0.90 SMN1; SMN2 (0.58) MAPTALDH1A1LMNAMAPK1TP53
SCHEMBL3016731 0.89 SMN1; SMN2 (0.48) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3015653 0.88 MAPT (0.61) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3017164 0.88 MAPT (0.61) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3006872 0.88 MAPT (0.61) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3012627 0.87 MAPK1 (0.56) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3010927 0.87 SMN1; SMN2 (0.46) MAPTALDH1A1LMNAMAPK1HSD17B10
SCHEMBL3015374 0.86 SMN1; SMN2 (0.58) MAPTALDH1A1MAPK1RECQLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.